How Are You Testing Your NASH Patients?
Why Is Risk-Stratification In NASH Patients Important?
In this 5-minute video, Dr. Sanyal discusses why risk-stratification of patients with advanced fibrosis due to NASH is so important and how he anticipates using the Enhanced Liver Fibrosis (ELF™) Test Enhanced Liver Fibrosis (ELF™) Test in his clinical practice.
The products/features mentioned here are not commercially available in all countries. Their future availability cannot be guaranteed.
In the U.S., the ELF Test is indicated as a prognostic marker in conjunction with other laboratory findings and clinical assessments in patients with advanced fibrosis (F3 or F4) due to nonalcoholic steatohepatitis (NASH) to assess the likelihood of progression to cirrhosis and liver-related clinical events.